JB Hi-Fi vs Harvey Norman shares: which dividend stock wins?

If you’re an Aussie investor eyeing retail stocks for dependable dividends, JB Hi-Fi Ltd (ASX: JBH) and Harvey Norman Holdings Ltd (ASX: HVN) quickly spring to mind. Both are household names selling consumer electronics and home essentials—but they each go about it a little differently, and their financial profiles pack in some key differences too. Comparing JB Hi-Fi vs Harvey Norman shares can help you decide which might suit your portfolio if you’re especially focused on dividend yield and income reliability. Let’s dig in.

The case for JB Hi-Fi

JB Hi-Fi is a leading specialty retailer focused mainly on consumer electronics, electrical appliances and white goods across Australia and New Zealand. Trading via JB Hi-Fi, JB Hi-Fi Home, The Good Guys and e&s, the company operates stores in shopping centres and standalone sites, with a digital presence that’s growing fast.

Notably, JB Hi-Fi offers:

• A market cap of $7.35 billion, making it significantly larger than Harvey Norman.
• A dividend yield of 5.16%, fully franked at 100%, with a history of special dividends.
• An earnings per share (EPS) of $4.467, reflecting robust underlying profitability.

JB Hi-Fi’s payout record is impressive—not only has the yield stayed attractive, its dividends have been fully franked for years, regularly delivering both interim and final (plus the occasional special) payments.

The case for Harvey Norman

Harvey Norman is best known as the powerhouse franchisor behind over 270 Harvey Norman, Domayne and Joyce Mayne stores. Its footprint isn’t limited to Australia; it stretches into New Zealand, Asia, and Europe. Uniquely, Harvey Norman also owns a hefty portfolio of properties that house many of its franchises, underpinning its balance sheet with hard assets.

Here’s where Harvey Norman stands out:

• A higher dividend yield of 7.02%, also fully franked at 100%.
• A lower P/E ratio of 9.75—suggesting shares are cheaper on earnings.
• Earnings yield of 10.26%, outpacing JB Hi-Fi.

While Harvey Norman’s market capitalisation ($5.25 billion) is smaller than JB Hi-Fi’s, it more than makes up for it with higher yield and an extensive property portfolio, providing another layer of security for income-seeking investors.

Valuation comparison

Metric	JB Hi-Fi	Harvey Norman
Market Cap	$7.35 billion	$5.25 billion
P/E Ratio	14.62	9.75
Dividend Yield	5.16% (100% franked)	7.02% (100% franked)
Dividend Per Share	$3.37	$0.26
Earnings Per Share	$4.467	$0.424
Earnings Yield	6.84%	10.26%

Harvey Norman sports a much higher yield, a lower price-to-earnings ratio and greater earnings yield, but JB Hi-Fi’s earnings and dividends per share are higher, reflecting JB Hi-Fi’s higher share price and perhaps greater operational scale.

Recent share price performance

Looking at recent momentum (prices as of mid-September 2026), both stocks have had a rocky year.

JB Hi-Fi shares have fallen -28.6% year to date, currently trading at $67.19.

Harvey Norman fared even worse, down 38.4% year to date, with shares sitting at $4.21.

In the most recent trading days, both have shown mild recoveries, but the medium-term trend has been negative for both companies—not uncommon among big-box retail shares facing tough consumer spending environments.

Which is the better buy?

If I’m choosing purely on dividend yield, Harvey Norman is the standout at 7.02%—well above JB Hi-Fi’s 5.16%. Both stocks offer fully franked dividends, which is excellent for Aussie income seekers. Harvey Norman also boasts a lower P/E and higher earnings yield, and its property ownership adds some ballast if retail trading turns rough.

On the other hand, JB Hi-Fi has demonstrated remarkable earnings power per share, a proven record of both ordinary and special dividends, and simply dwarfs Harvey Norman on a per-share dividend basis, even if its headline yield is lower due to a high share price.

Both companies have had a rough run lately, but Harvey Norman’s share price has fallen more steeply—potentially making that big yield even more attractive, but also possibly reflecting some market concern.

If I had to place my chips, I’d lean toward Harvey Norman solely for the yield and value metrics, especially if I wanted maximum income right now. But for consistency, payout reliability, and a stronger track record of per-share earnings, my confidence would sway toward JB Hi-Fi over the long term. It’s very close—and I couldn’t fault an investor for favouring either, but for a high franked yield in today’s market, my pick would be Harvey Norman.

The post JB Hi-Fi vs Harvey Norman: Which dividend stock wins? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• 2 ASX blue-chip shares offering big dividend yields
• Top 3 ASX 200 shares now below their 200-day moving average
• JB Hi-Fi, GPT Group, Charter Hall shares hit 52-week low: Is there any chance of a rebound?
• Why the ASX 200 just hit a 6-week low

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Harvey Norman. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial draft. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Shares in Neurizon Therapeutics Ltd (ASX: NUZ) are down about 45% over the past 12 months, but according to the team at Morgans, there is potentially good upside in the stock.

Key hire a positive sign

Morgans has just released a new research report on the company and reiterated its bullish share price target on the company, which I’ll get to shortly.

The broker has revisited Neurizon because the company released three news announcements in quick succession earlier this month.

Arguably, the most impactful of these was the hiring of a new Chief Executive Officer, Dr Chris Bremer, who has more than 20 years’ leadership experience spanning drug development, portfolio strategy, commercialisation, and business development.

Neurizon said that during his career, Dr Bremer had been involved in more than US$1 billion worth of licensing transactions.

The company said:

He has extensive experience guiding pharmaceutical assets from early development through to product launch and lifecycle management, as well as evaluating and executing licensing and strategic partnership transactions. His appointment comes as Neurizon advances NUZ-001 through Regimen I of the registrational Phase 2/3 HEALEY ALS Platform Trial and enters the important period leading up to topline results, expected in late Q2 CY2027. His combination of scientific, medical, commercial and transactional experience is particularly relevant as the Company prepares for the potential regulatory, development and strategic pathways that may follow and seeks to create long term shareholder value.

Neurizon’s lead investigational therapy, NUZ-001, is being evaluated as a treatment for ALS in 250 participants.

The company said its priorities “include disciplined execution of the clinical program through to topline results, continued regulatory … readiness, further development of the scientific evidence supporting NUZ-001, and preparation for potential development, partnering and commercial pathways, subject to the outcomes of the study”.

Shares looking cheap according to Morgans

Morgans said they saw Dr Bremer’s hiring as a signal that the company was looking to find development partners.

They said:

The company is unlikely to recruit a US$1bn-plus licensing operator two quarters from a registrational readout unless the Board is building toward that outcome as the preferred path. Dr Bremer has worked both sides of the licensing fence, inbound and outbound, so his skillset should be useful in structuring the dataroom, shaping the partnering process and negotiating economics if the topline result is positive.

Morgans has a price target on Neurizon of 20 cents per share compared to the current share price of 7.5 cents.

Their totally unrisked valuation is $1.50 per share, while should the clinical trial be a failure, the valuation drops to 1 to 2 cents.

Neurizon is valued at $59.4 million.    

The post Could this ASX biotech really jump more than 150%? One broker thinks so appeared first on The Motley Fool Australia.

More reading

• Why did the Bitcoin price just plunge 6%?
• How much passive income could I earn from a $650,000 superannuation balance?
• Down 6% today: What’s going on with the James Hardie share price?
• JB Hi-Fi vs Harvey Norman: Which dividend stock wins?
• Why this ASX share is a retiree’s dream for FY27

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The ASX share Charter Hall Long WALE REIT (ASX: CLW) looks to me like a top pick for retirees and anyone wanting passive income.

Commercial property typically offers a much higher rental yield than residential property, allowing it to provide investors with attractive passive income.

Real estate investment trusts (REITs) are the structure that allows investors to invest in commercial property on the ASX.

For me, Charter Hall Long WALE REIT is one of the leading picks for retirees for a number of reasons.

Diversification

The business can offer investors significant diversification because it’s invested across a number of key defensive tenant industries that are supposedly resilient to economic shocks.

It’s invested in areas that have tenants across government areas (like Geosciences Australia), hotels, grocery and distribution, telecommunications exchanges, data centres, service stations, banking and professional services, food manufacturing, healthcare, Bunnings properties, and more.

To be able to make one investment and get exposure to all of those sectors sounds appealing to me.

In terms of the quality of tenants, the organisations that account for at least 5% of revenue include government entities, Endeavour Group Ltd (ASX: EDV), Telstra Group Ltd (ASX: TLS), BP, Coles Group Ltd (ASX: COL) and Metcash Ltd (ASX: MTS).

The tenants are signed on for long-term contracts, giving investors long-term income security. Charter Hall Long WALE REIT currently has a weighted average lease expiry (WALE) of around nine years, which is a comforting length of time for retirees.

Ongoing rental growth

A REIT is not a term deposit; it’s capable of delivering growth for investors.

The business has rental growth built into its contracts, which is a good tailwind for both rising property values and increasing the distribution over time.

Some of the properties have rental income growth linked to inflation, while the rest have fixed annual increases. This combination helped the business achieve average annual net property income growth of 3.1% in FY26.

I think rising rental income is a key factor that helped the business report a 2.6% year-over-year improvement in net tangible assets (NTA) during FY26.

Strong passive income yield

The business has a very generous distribution payout ratio of 100% of its rental earnings, giving investors a large yield.

It’s also trading at a large discount to its underlying value – the NTA was $4.71 as of 30 June 2026. That means it’s trading at a 28% discount, which is enormous for a high-quality REIT, in my view.

The ASX share expects to pay an annual distribution of 25.5 cents per security in FY27, which translates into a distribution yield of 7.5%. I think that’s very appealing, and I’d happily buy some units if I were a retiree.

The post Why this ASX share is a retiree’s dream for FY27 appeared first on The Motley Fool Australia.

More reading

• How to make $26,000 of passive income from ASX shares
• How much is needed in superannuation to target a $6,500 monthly passive income?
• How much superannuation is needed to target $5,500 per month in passive income?
• How much is needed in superannuation to target a $70,000 annual passive income?
• 2 ASX blue-chip shares offering big dividend yields

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended BP. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.